Join Medical Oncologist Professor Bogda Koczwara AM and Dr. David Mizrahi,  Exercise Physiologist and Research Fellow at the Daffodil Center, University of Sydney, to explore why movement matters for patients with cancer ..read more

There’s still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects. While responsible for saving many lives, this treatment sometimes causes cardiac damage that stiffens the heart and puts a subset of patients at risk for future heart failure. To better understand and potentially control such complications, Tufts University ..read more

Published in PNAS, a research team led by the University of Minnesota Medical School, USA, demonstrated that the socioeconomic status (SES) of cell donors affects the health outcomes of blood cancer patients who underwent haematopoietic cell transplantation (HCT). The study examined the health outcomes of 2,005 blood cancer patients treated with HCT across 125 hospitals in ..read more

A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University Chobanian & Avedisian School of Medicine, USA, found that women with severe endometriosis are 10 times more likely to get ovarian cancer, compared to women who ..read more

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality worldwide. Patients diagnosed with HCC face low survival rates, around 10% surviving for five years, often experience cancer recurrence and lack effective anti-cancer drugs. Given the liver’s vital role in metabolism, HCC treatment aims to prevent tumours while preserving liver function. Since cancer-driving ..read more

Current screening protocols fail to catch a notable number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome and Lynch syndrome, which increase the risk of developing certain cancers. This issue is particularly pronounced among underrepresented minorities. These research findings, published in JCO Precision Oncology, are based on genetic screenings of more than ..read more

How does a normal cell in the body develop into an aggressive cancer cell? According to the central tumour model, cancer develops in an evolutionary process. When randomly distributed mutations in cancer genes accumulate in single cells, this gradually perturbs cell division and other cellular properties until the control programs get out of hand. These ..read more

A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to new findings from the University of Missouri School of Medicine (USA) published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Despite surgical and chemotherapy treatment, more than 50% of non-metastatic, non-small ..read more

University of Pittsburgh and UPMC Hillman Cancer Center researchers in the USA, have developed a novel prompt, or ‘nudge’ embedded in the electronic health record that flags, for treating surgeons, older patients with early-stage breast cancer who may be at risk for unnecessary lymph node surgery. In a paper published today in JAMA Surgery, the team ..read more

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumour-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential. “TIL therapy represents a major advancement in personalised cancer treatment ..read more